Lung cancer is the leading cause of cancer-related death in the United States, accounting
for over 30% of cancer deaths in men and 25% in women. Small-cell lung cancer (SCLC) …

The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC
is nearly universally smoking-related and is very sensitive to both chemotherapy and …

Although small-cell lung cancer (SCLC) makes up a smaller proportion of all lung cancers
than it did 25 years ago, it remains a common cause of cancer mortality that requires more …

Despite recent progress in the development of new molecularly targeted agents, the
chemotherapy regimens considered standard at the end of the last century—that is, two-drug …

Despite the very good response rate of small cell lung cancer (SCLC) to many anti-cancer
agents, survival remains disappointing, particularly in extensive-stage (ES) disease. Many …

Systemic chemotherapy with platinum-based combinations provides modest improvements
in both survival and quality of life for patients with advanced non-small cell lung cancer …

Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such
as etoposide) and carboplatin is an effective and safe first-line treatment for patients with …

Background: The combination of cisplatin and etoposide (PE) has been a standard
treatment for patients with poor-prognosis small cell lung cancer (SCLC). This non-inferiority …

Although small-cell lung cancer (SCLC) represents only 20% of all lung cancer cases in the
United States, it is the most lethal subtype. Combination chemotherapy unequivocally offers …

Background: Lung cancer remains a devastating disease with few effective treatment
options. Recent developments in chemotherapy have led to cautious optimism. This paper …